{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:04:21Z","timestamp":1789761861074,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[1991,11,1]],"date-time":"1991-11-01T00:00:00Z","timestamp":688953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1991,11,1]],"date-time":"1991-11-01T00:00:00Z","timestamp":688953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1991,11]]},"DOI":"10.1136\/ard.50.11.800","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T23:49:46Z","timestamp":1217288986000},"page":"800-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases."],"prefix":"10.1016","volume":"50","author":[{"given":"H.I","family":"Torley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Madhok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A","family":"Capell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J","family":"Maddison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Englert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A","family":"Dormandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref_1","first-page":"1299","article-title":"Controlled trial of nifedipine in the treatment of Raynaud's phenomenon","volume":"ii:","author":"D, Smith C.; R, McKendry R.J.","year":"1982","unstructured":"Smith C D, McKendry R J R. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982; ii: 1299-301.","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-94-4-546_1","article-title":"Nifedipine in the treatment of Raynaud's syndrome","volume":"94","author":"Kahan, A.","year":"1981","unstructured":"Kahan A. Nifedipine in the treatment of Raynaud's syndrome. Ann Intern Med 1981; 94: 546.","journal-title":"Ann Intern Med"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/art.1780270204","article-title":"Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5HT2) receptor","volume":"27","author":"R, Siebald J.; M, Jageneau A.H.","year":"1984","unstructured":"Siebald J R, Jageneau A H M. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5HT2) receptor. Arthritis Rheum 1984; 27: 139-46.","journal-title":"Arthritis Rheum"},{"key":"ref_4","first-page":"523","article-title":"Treatment of Raynaud's phenomenon by fibrinolytic enhancement","volume":"ii:","author":"M, Jarrett P.E.; M, Merland; L, Browse N.","year":"1978","unstructured":"Jarrett P E M, Merland M, Browse N L. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. BMJ 1978; ii: 523-5.","journal-title":"BMJ"},{"key":"ref_5","first-page":"313","article-title":"Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome","volume":"i:","author":"F, Belch J.J.; K, Drury J.; A, Capell H.","year":"1983","unstructured":"Belch J J F, Drury J K, Capell H A, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1983; i: 313-7.","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/rheumatology\/27.3.220","article-title":"Successful treatment ofRaynaud's syndrome with iloprost, a chemically stable prostacyclin analogue","volume":"27","author":"A, Yardumian D.; A, Isenberg D.; M, Rustin","year":"1988","unstructured":"Yardumian D A, Isenberg D A, Rustin M, et al. Successful treatment ofRaynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988; 27: 220-6.","journal-title":"Br J Rheumatol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.47.1.43","article-title":"Infusion of iloprost, a prostacyclin analogue, for treatment ofRaynaud's phenomenon in systemic sclerosis","volume":"47","author":"J, McHugh N.; M, Csuka; R, Watson H.","year":"1988","unstructured":"McHugh N J, Csuka M, Watson H R, et al. Infusion of iloprost, a prostacyclin analogue, for treatment ofRaynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988; 47: 43-7.","journal-title":"Ann Rheum Dis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker, M.; D, Cooke E.; E, Almond N.","year":"1989","unstructured":"Rademaker M, Cooke E D, Almond N E, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298: 561-4.","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/pgmj.63.742.617","article-title":"increase in digital blood flow following iloprost infusion in patients with systemic sclerosis","volume":"63","author":"Rademaker, M.","year":"1987","unstructured":"Rademaker M, Thomas R H M, Provost G, Beacham J A, Cooke E D, Kirby J D. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987; 63: 617-20.","journal-title":"Postgrad Med J"},{"key":"ref_10","first-page":"184","article-title":"Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E, on human platelet function","volume":"109","author":"A, Fisher C.; R, Kappa J.; K, Sinha A.; D, Cottrell E.; J, Reiser H.; P, Addonizio V.","year":"1987","unstructured":"Fisher C A, Kappa J R, Sinha A K, Cottrell E D, Reiser H J, Addonizio V P. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E, on human platelet function. J Lab Clin Med 1987; 109: 184-90.","journal-title":"J Lab Clin Med"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0090-6980(86)90225-X","article-title":"Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease","volume":"31","author":"Musial, J.; Wilczynska, M.; Sladek, K.; S, Cierniawski C.; Nizankowski, R.; Szczeklik, A.","year":"1986","unstructured":"Musial J, Wilczynska M, Sladek K, Cierniawski C S, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986; 31: 61-70.","journal-title":"Prostaglandins"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0038-1647018","article-title":"Defective fibrinolytic response in atherosclerotic patients-effect of iloprost and its possible mechanism of action","volume":"60","author":"Bertele, V.; Mussoni, L.; del Rosso, G.","year":"1988","unstructured":"Bertele V, Mussoni L, del Rosso G, et al. Defective fibrinolytic response in atherosclerotic patients-effect of iloprost and its possible mechanism of action. Thromb Haemost 1988; 60: 141-4.","journal-title":"Thromb Haemost"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi, A.; Rodnan, G.; A, Medsger T.","year":"1980","unstructured":"Masi A, Rodnan G, Medsger T A, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.","journal-title":"Arthritis Rheum"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.1780270202","article-title":"anticentromere antibody in patients with progressive systemic sclerosis","volume":"27","author":"D, Steen V.; L, Ziegler G.; P, Rodnan G.; A, Jr, Medsger T.","year":"1984","unstructured":"Steen V D, Ziegler G L, Rodnan G P, Medsger T A Jr. Clinical and laboratory association of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984; 27: 125-31.","journal-title":"Arthritis Rheum"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.1983.tb01544.x","article-title":"Uses and abuses of analysis of variance","volume":"15","author":"W, Evans S.J.","year":"1983","unstructured":"Evans S J W. Uses and abuses of analysis of variance. BrJ Clin Pharmacol 1983; 15: 629-48.","journal-title":"BrJ Clin Pharmacol"},{"key":"ref_16","article-title":"Scleroderma (systemic sclerosis): treatment and clinical manifestations as related to pathogenesis","volume-title":"Cohen A S, ed. Progress in clinical rheumatolo. Vol 1","author":"B, Kahaleb M.; C, Lekey E.","year":"1984","unstructured":"Kahaleb M B, Lekey E C. Scleroderma (systemic sclerosis): treatment and clinical manifestations as related to pathogenesis. In: Cohen A S, ed. Progress in clinical rheumatolo. Vol 1. New York: Grune and Stratton, 1984."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/003693308703200106","article-title":"Abnormal biochemical and cellular parameters in the blood of patients with Raynaud's phenomenon","volume":"32","author":"F, Belch J.J.; J, Drury; K, McLaughlin","year":"1987","unstructured":"Belch J J F, Drury J, McLaughlin K, et al. Abnormal biochemical and cellular parameters in the blood of patients with Raynaud's phenomenon. Scott Med 1987; 32: 12-14.","journal-title":"Scott Med"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0262-1746(85)90029-0","article-title":"Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome","volume":"17","author":"F, Belch J.J.; M, McLaren; J, Anderson","year":"1985","unstructured":"Belch J J F, McLaren M, Anderson J, et al. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukot Med 1985; 17: 1-9.","journal-title":"Prostaglandins Leukot Med"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/ard.44.2.73","article-title":"Prostaglandin El, vasospastic disease and thermography","volume":"44","author":"Kyle, V.; Parr, G.; Salisbury, R.; P, Thomas P.; Hazleman, B.","year":"1985","unstructured":"Kyle V, Parr G, Salisbury R, Thomas P P, Hazleman B. Prostaglandin El, vasospastic disease and thermography. Ann Rheum Dis 1985; 44: 73-8.","journal-title":"Ann Rheum Dis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0038-1650182","article-title":"Successful treatment of Raynaud's syndrome with prostacyclin","volume":"45","author":"F, Belch J.J.; P, Newman; K, Drury J.","year":"1981","unstructured":"Belch J J F, Newman P, Drury J K, et al. Successful treatment of Raynaud's syndrome with prostacyclin. Thromb Haemost 1981; 45: 255-6.","journal-title":"Thromb Haemost"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2133.1982.tb00905.x","article-title":"Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)","volume":"106","author":"M, Dowd P.; R, Martin M.F.; D, Cooke E.","year":"1982","unstructured":"Dowd P M, Martin M F R, Cooke E D, et al. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). BrJ Dermatol 1982; 106: 81-9.","journal-title":"BrJ Dermatol"},{"key":"ref_22","first-page":"350","article-title":"Effect of deformablity patsentswis th Rayn2auad's pEhlenoonmerneodn acenld systemic in sclerosis","volume":"283","author":"M, Dowd P.; B, Kovacs I.; H, Bland C.J.; T, Kirby J.D.","year":"1981","unstructured":"Dowd P M, Kovacs I B, Bland C J H, Kirby J D T. Effect of deformablity patsentswis th Rayn2auad's pEhlenoonmerneodn acenld systemic in sclerosis. BM 1981; 283: 350."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-642-71499-3_2","article-title":"Chemistry of stable prostacyclin analgues: synthesis ofiloprost","volume-title":"its stable analogue iloprost","author":"Skuballa, W.; Raduchel, B.; Vorbruggen, H.","year":"1987","unstructured":"Skuballa W, Raduchel B, Vorbruggen H. Chemistry of stable prostacyclin analgues: synthesis ofiloprost. In: Gryglewski R J, Stock G, eds. Prostacyclin and its stable analogue iloprost. Berlin, Heidelberg: Springer, 1987: 17-24."},{"key":"ref_24","first-page":"672","article-title":"Inhibition of polymorphonuclear leukocyte adherence by prostacyclin","volume":"95","author":"A, Boxer L.; M, Allen J.; M, Schmidt; M, Toder; L, Bachner R.","year":"1980","unstructured":"Boxer L A, Allen J M, Schmidt M, Toder M, Bachner R L. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. Lab Clin Med 1980; 95: 672-8.","journal-title":"Lab Clin Med"},{"key":"ref_25","first-page":"97","article-title":"Effect of iloprost ZK 36374 on white cell behaviour","volume-title":"its stable analogue iloprost","author":"F, Belch J.J.; A, Saniabadi; R, Dickson; D, Sturrock R.; D, Forbes C.","year":"1987","unstructured":"Belch J J F, Saniabadi A, Dickson R, Sturrock R D, Forbes C D. Effect of iloprost ZK 36374 on white cell behaviour. In: Gryglewski R J, Stock G, eds. Prostacclin and its stable analogue iloprost. Berlin, Heidelberg: Springer, 1987: 97-102."},{"key":"ref_26","first-page":"1180","article-title":"Double-blind trial of CLIl5, 347, a transdermally absorbed prostaglandin E2 analogue in the treatment of Raynaud's phenomenon","volume":"i:","author":"F, Belch J.J.; B, Shaw; R, Madhok; P, Leiberman D.; D, Sturrock R.; D, Forbes C.","year":"1985","unstructured":"Belch J J F, Shaw B, Madhok R, Leiberman D P, Sturrock R D, Forbes C D. Double-blind trial of CLIl5, 347, a transdermally absorbed prostaglandin E2 analogue in the treatment of Raynaud's phenomenon. Lancet 1985; i: 1180-3.","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724105675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724105675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.50.11.800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:51:53Z","timestamp":1737445913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724105675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1991,11]]}},"alternative-id":["S0003496724105675"],"URL":"https:\/\/doi.org\/10.1136\/ard.50.11.800","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[1991,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.50.11.800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1991 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}